99 related articles for article (PubMed ID: 38478885)
1. Electrophilic PROTACs that degrade nuclear proteins by engaging DCAF16.
Zhang X; Crowley VM; Wucherpfennig TG; Dix MM; Cravatt BF
Nat Chem Biol; 2019 Jul; 15(7):737-746. PubMed ID: 31209349
[TBL] [Abstract][Full Text] [Related]
2. Application of AlphaFold models in evaluating ligandable cysteines across E3 ligases.
Koldenhof P; Bemelmans MP; Ghosh B; Damm-Ganamet KL; van Vlijmen HWT; Pande V
Proteins; 2024 Jul; 92(7):819-829. PubMed ID: 38337153
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and biological evaluation of niclosamide PROTACs.
Munoz E; Chen G; Hossain A; Wu S; Oceguera Nava E; Hang J; Lee T; Zhang Q; Wang G; Chen QH
Bioorg Med Chem Lett; 2022 Sep; 72():128870. PubMed ID: 35772635
[TBL] [Abstract][Full Text] [Related]
4. Ternary Complex-Templated Dynamic Combinatorial Chemistry for the Selection and Identification of Homo-PROTACs.
Diehl CJ; Salerno A; Ciulli A
Angew Chem Int Ed Engl; 2024 Jun; 63(25):e202319456. PubMed ID: 38626385
[TBL] [Abstract][Full Text] [Related]
5. Development of DNA Aptamer-Based PROTACs That Degrade the Estrogen Receptor.
Tsujimura H; Naganuma M; Ohoka N; Inoue T; Naito M; Tsuji G; Demizu Y
ACS Med Chem Lett; 2023 Jun; 14(6):827-832. PubMed ID: 37312841
[TBL] [Abstract][Full Text] [Related]
6. Preparation of von Hippel-Lindau (VHL) E3 ubiquitin ligase ligands exploiting constitutive hydroxyproline for benzylic amine protection.
Soto-Martínez DM; Clements GD; Díaz JE; Becher J; Reynolds RC; Ochsenbauer C; Snowden TS
RSC Adv; 2024 May; 14(24):17077-17090. PubMed ID: 38808246
[TBL] [Abstract][Full Text] [Related]
7. Plasticity in binding confers selectivity in ligand-induced protein degradation.
Nowak RP; DeAngelo SL; Buckley D; He Z; Donovan KA; An J; Safaee N; Jedrychowski MP; Ponthier CM; Ishoey M; Zhang T; Mancias JD; Gray NS; Bradner JE; Fischer ES
Nat Chem Biol; 2018 Jul; 14(7):706-714. PubMed ID: 29892083
[TBL] [Abstract][Full Text] [Related]
8. Discovery of a DCAF11-dependent cyanoacrylamide-containing covalent degrader of BET-proteins.
Tin G; Cigler M; Hinterndorfer M; Dong KD; Imrichova H; Gygi SP; Winter GE
Bioorg Med Chem Lett; 2024 Jul; 107():129779. PubMed ID: 38729317
[TBL] [Abstract][Full Text] [Related]
9. Click chemistry in the development of PROTACs.
Yang C; Tripathi R; Wang B
RSC Chem Biol; 2024 Mar; 5(3):189-197. PubMed ID: 38456041
[TBL] [Abstract][Full Text] [Related]
10. Lysineless HiBiT and NanoLuc Tagging Systems as Alternative Tools Monitoring Targeted Protein Degradation.
Lin H; Riching K; Lai MP; Lu D; Cheng R; Qi X; Wang J
bioRxiv; 2024 May; ():. PubMed ID: 38798562
[TBL] [Abstract][Full Text] [Related]
11. Potency-Enhanced Peptidomimetic VHL Ligands with Improved Oral Bioavailability.
Wu H; Murray J; Ishisoko N; Frommlet A; Deshmukh G; DiPasquale A; Mulvihill MM; Zhang D; Quinn JG; Blake RA; Fairbrother WJ; Fuhrmann J
J Med Chem; 2024 May; ():. PubMed ID: 38809766
[TBL] [Abstract][Full Text] [Related]
12. Characterisation of high throughput screening outputs for small molecule degrader discovery.
Bell LE; Bardelle C; Packer MJ; Kastl J; Holdgate GA; Davies G
SLAS Discov; 2024 May; 29(5):100162. PubMed ID: 38797285
[TBL] [Abstract][Full Text] [Related]
13. Covalent Degrader of the Oncogenic Transcription Factor β-Catenin.
Gowans FA; Forte N; Hatcher J; Huang OW; Wang Y; Altamirano Poblano BE; Wertz IE; Nomura DK
J Am Chem Soc; 2024 Jun; ():. PubMed ID: 38848252
[TBL] [Abstract][Full Text] [Related]
14. Breaking Bad Proteins-Discovery Approaches and the Road to Clinic for Degraders.
Bouvier C; Lawrence R; Cavallo F; Xolalpa W; Jordan A; Hjerpe R; Rodriguez MS
Cells; 2024 Mar; 13(7):. PubMed ID: 38607017
[TBL] [Abstract][Full Text] [Related]
15. Structure-Guided Design and Optimization of Covalent VHL-Targeted Sulfonyl Fluoride PROTACs.
Shah RR; De Vita E; Sathyamurthi PS; Conole D; Zhang X; Fellows E; Dickinson ER; Fleites CM; Queisser MA; Harling JD; Tate EW
J Med Chem; 2024 Mar; 67(6):4641-4654. PubMed ID: 38478885
[TBL] [Abstract][Full Text] [Related]
16. Journey of Von Hippel-Lindau (VHL) E3 ligase in PROTACs design: From VHL ligands to VHL-based degraders.
Setia N; Almuqdadi HTA; Abid M
Eur J Med Chem; 2024 Feb; 265():116041. PubMed ID: 38199162
[TBL] [Abstract][Full Text] [Related]
17. A beginner's guide to current synthetic linker strategies towards VHL-recruiting PROTACs.
Zografou-Barredo NA; Hallatt AJ; Goujon-Ricci J; Cano C
Bioorg Med Chem; 2023 Jun; 88-89():117334. PubMed ID: 37224698
[TBL] [Abstract][Full Text] [Related]
18. E3 Ligase Ligands for PROTACs: How They Were Found and How to Discover New Ones.
Ishida T; Ciulli A
SLAS Discov; 2021 Apr; 26(4):484-502. PubMed ID: 33143537
[TBL] [Abstract][Full Text] [Related]
19. Targeted Protein Degradation through E2 Recruitment.
Forte N; Dovala D; Hesse MJ; McKenna JM; Tallarico JA; Schirle M; Nomura DK
ACS Chem Biol; 2023 Apr; 18(4):897-904. PubMed ID: 36940189
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
